{
    "nct_id": "NCT03582774",
    "official_title": "Phase III Randomized Multicenter Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT]",
    "inclusion_criteria": "* Histopathology proven prostate cancer.\n* Planned SRT for recurrence after primary prostatectomy.\n* Prostate-specific antigen (PSA) >= 0.1 ng/ml at time of enrollment.\n* Willingness to undergo radiotherapy.\n* Treating radiation oncologist intends to incorporate 68Ga-PSMA-11 PET/CT findings into the radiotherapy plan if patient undergoes 68Ga-PSMA-11 PET/CT.\nHealthy volunteers allowed\nMust be MALE",
    "exclusion_criteria": "* Extra-pelvic metastasis on any imaging or biopsy.\n* Androgen deprivation therapy (ADT) within 3 months before 68Ga-PSMA-11 PET/CT.\n* Contraindications to radiotherapy (including active inflammatory bowel disease).\n* Concurrent systemic therapy for prostate cancer with investigational agents.",
    "miscellaneous_criteria": ""
}